PLpro inhibitor

• UNSPSC Description:

  PLpro inhibitor is a potent inhibitor of papain-like protease (PLpro) with an IC50 of 2.6 μM[1]. PLpro inhibitor inhibits SARS-CoV-2 PLpro with an IC50 of 5.0 μM and an EC50 of 21.0 μM[2].

• Target Antigen:

  SARS-CoV

• Type:

  Reference compound

• Related Pathways:

  Anti-infection

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Infection

• Assay Protocol:

  https://www.medchemexpress.com/PLpro-inhibitor.html

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  O=C(C1=CC(NC(C)=O)=CC=C1C)N[C@H](C)C2=C(C=CC=C3)C3=CC=C2

• Molecular Weight:

  346.42

• References & Citations:

  [1]Ratia, K., et al., A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication. Proc Natl Acad Sci U S A, 2008. 105(42): p. 16119-24.|[2]http://www.google.com/patents/WO2010022355A1cl=en|[3]Brendan T Freitas, et al. Characterization and Noncovalent Inhibition of the Deubiquitinase and deISGylase Activity of SARS-CoV-2 Papain-Like Protease. ACS Infect Dis. 2020 May 19.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  1093070-14-4